Table 4.
Univariate Cox regression analyses of prognostic factors in Uyghur NPC patients
| Factors | 3-year OS | 3-year DFS | 3-year DMFS | 3-year LRFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| HLA-DRB1*0701 status | 0.891 | 0.208 | 0.651 | 0.857 | ||||
| HLA-DRB1*0701 | 1 | 1 | 1 | 1 | ||||
| Non-HLA-DRB1*0701 | 0.882 (0.146–5.311) | 2.977 (0.544–16.289) | 1.377 (0.344–5.510) | 1.180 (0.196–7.117) | ||||
| Gender | 0.428 | 0.729 | 0.455 | 0.584 | ||||
| Male | 1 | 1 | 1 | 1 | ||||
| Female | 0.412 (0.046–3.697) | 0.740 (0.135–4.065) | 0.543 (0.109–2.699) | 0.531 (0.055–5.123) | ||||
| Age | 0.361 | 0.242 | 0.233 | 0.290 | ||||
| <45 years | 1 | 1 | 1 | 1 | ||||
| ≥45 years | 2.316 (0.383–14.018) | 2.614 (0.524–13.056) | 2.332 (0.580–9.386) | 2.637 (0.437–15.919) | ||||
| Histological classification | 0.332 | 0.292 | 0.162 | 0.333 | ||||
| Differentiated type | 1 | 1 | 1 | 1 | ||||
| Nondifferentiated type | 42.742 (0.022–84,224.802) | 3.188 (0.369–27.580) | 4.466 (0.547–36.430) | 42.585 (0.021–85,148.450) | ||||
| Clinical stage | 0.676 | 0.674 | 0.617 | 0.579 | ||||
| I + II | 1 | 1 | 1 | 1 | ||||
| III + IV | 22.770 (0.000–5.362×107) | 22.280 (0.000–4.170×107) | 22.422 (0.000–4,337,407.866) | 29.711 (0.000–4,810,491.419) | ||||
| T-stage | 0.535 | 0.943 | 0.492 | |||||
| T1 + T2 | 1 | 1 | 1 | 0.847 | 1 | |||
| T3 + T4 | 26.478 (0.001–834,943.116) | 0.925 (0.108–7.931) | 1.229 (0.151–10.001) | 29.732 (0.002–478,273.514) | ||||
| N-stage | 0.509 | 0.725 | 0.589 | 0.470 | ||||
| N0 + N1 | 1 | 1 | 1 | 1 | ||||
| N2 + N3 | 27.888 (0.001–538,949.647) | 1.471 (0.171–12.629) | 1.783 (0.219–14.541) | 30.767 (0.003–332,472.900) | ||||
NPC: Nasopharyngeal carcinoma; HLA: Human leukocyte antigen; OS: Overall survival; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; LRFS: Local relapse-free survival; HR: Hazard ratio; CI: Confidence interval.